

Quarterly Results and Investor Conference Call Notification

July 12, 2018 – Melbourne, Australia – Osprey Medical (ASX:OSP) today advises it will release its Appendix 4C Quarterly Cash Flow Report for the period ending 30 June 2018, on Thursday 19th July 2018.

Investors are invited to join a conference call hosted by CEO Mike McCormick on Thursday 19th July 2018 at 9:00am Australian Eastern Standard Time (7:00am Hong Kong/Singapore, 6pm Wednesday 18th July 2018 US Minneapolis, MN).

To pre-register, please follow this link:

<https://services.choruscall.com.au/diamondpass/ospreymedical-459649-invite.html>

You will receive a calendar notification with dial-in details and a PIN for fast track access to the call.

Contact details:

Media

Andrew Hamilton
Mana Communications
T: (61) 420 447 669
ah@manacomunications.com

Investors

Kyahn Williamson
WEBuchan
M: (61) 401018828
kwilliamson@we-buchan.com

Company

Doug Schoenberg
VP of Marketing
T: (952) 955 8230
dschoenberg@ospreymed.com

About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast Induced Acute Kidney Injury (AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ Plus System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.